Raman Pharma is a UK based MHRA and VMD Licensed Wholesaler supplying to the Human and Veterinary Market. We are a family run company ambitiously changing the face of the Pharmaceutical and Veterinary Market alike in order to serve the needs of our customers and their patients.
Our Philosophy and business are structured around the requirements of our customers and we are committed to giving them our upmost attention and care. We believe in delivering quality and value to our customers wherever they may be.
The Herbal Horse and Pet is a South African manufacturer of a very innovative range of supplements for horses, dogs and cats. Their philosophy of using a large number of different ingredients in small amounts mimics nature in that the healing effect of the ingredients is maximised while undesirable side-effects are minimised. These unique formulations, in conjunction with 21st century scientific research and techniques are what they call “cutting edge nature”.
They are manufactured in a GMP Compliant Factory and has a large following from riders and pet owners across the world. Please follow the link to the website – www.theherbalhorse.co.uk to see all the amazing blogs and the ability to purchase these products online. The Equine and Pet Range were introduced to the UK Market in September 2014 by Raman Pharma to give the UK a taste of the future in equine and companion animal nutritional supplements.
"Fantastic service, Really helpful & always able to source products that we need at very competitive prices. Would thoroughly recommend to any Veterinary Practice"
"Raman Pharma have been invaluable in sourcing drugs that are out of stock elsewhere. Delivery is rapid, costs are good and the customer service provided by Dhruv is excellent. I would definitely recommend this company and its services to others."
PSNC Chief Executive Simon Dukes has recorded a new video message for community pharmacy contractors and their teams. In the video Simon reflects on the extraordinary year just passed and looks to the challenges ahead, noting in particular the stoicism and commitment of community pharmacy teams and calling for an end to the slow responses...
The Department of Health and Social Care (DHSC) has today granted the following initial list of price concessions: Drug Pack Size Price Concession Ciprofloxacin 500mg tablets 10 £3.85 Duloxetine 20mg gastro-resistant capsules 28 £8.68 Duloxetine 30mg gastro-resistant capsules 28 £2.39 Duloxetine 60mg gastro-resistant capsules 28 £3.99 Enalapril 10mg tablets 28 £6.10 Enalapril 20mg tablets 28...
NHS England and NHS Improvement (NHSE&I) have today (15th January 2021), published the NHS Discharge Medicines Service (DMS) Toolkit for Pharmacy Staff in Community, Primary and Secondary Care. The toolkit aims to assist and support cross sector implementation of the DMS as an Essential service in all NHS community pharmacies in England. It sets out...
Department of Health and Social Care (DHSC) has issued a Medicine Supply Notification (MSN) for Sancuso (granisetron) 3.1mg/24 hours transdermal patches Sancuso® (granisetron) 3.1mg/24 hours transdermal patches are out of stock until mid-February 2021 (other formulations of granisetron (tablets and injection) are not affected). Specialist importer companies have indicated that unlicensed imports of granisetron 3.1mg/24hours...
Update (14/01/2020): Normacol granules back in stock, Normacol Plus granules now expected early February 2021 Department of Health and Social Care (DHSC) has issued a medicine supply notification for Sterculia (Normacol) 62% w/w granules, Sterculia & Frangula Bark (Normacol Plus) 62%/8% w/w granules Normacol and Normacol Plus granules are out of stock until 13th September...
Update: (14/01/2020) resupply now expected End of March 2021 Department of Health and Social Care (DHSC) has today issued a medicine supply notification for Fluoxetine 30mg capsules (Advanz) Advanz, the sole supplier, are out of stock of fluoxetine 30mg capsules with resupply expected mid-December 2020 Fluoxetine 10mg and 20mg capsules remain available A Serious...
Update (14/01/2021) – Due to changes in the availability of Bisacodyl suppositories – an updated overview can be found below: Product Supplier Current Stock Position Anticipated resupply date Bisacodyl 5mg suppositories Sanofi Out of stock Early March 2021 Bisacodyl 10mg suppositories Sanofi Out of stock Limited supplies expected early February 2021, full resupplies expected March...
Update: 14/01/2021 Resupply date now expected to be End of January 2021 Department of Health and Social Care (DHSC) has issued a medicine supply notification for Prednisolone 5mg suppositories. Prednisolone 5mg suppositories are out of stock until end of July 2020 due to manufacturing issues. Unlicensed supplies of prednisolone 5mg suppositories have been sourced, lead...
The Department of Health and Social Care (DHSC) has confirmed that from tomorrow (15th January 2021), community pharmacies can offer a flu vaccination using DHSC centrally procured vaccine to private patients or those within occupational health schemes (Group C patients in the DHSC guidance on use of centrally procured vaccines). This decision follows PSNC’s request...
The Home Office is implementing a new scheme to help victims of domestic abuse access support safely, and is encouraging community pharmacy teams to get involved. The ‘Ask for ANI’ scheme has been developed by the Home Office to provide a simple and discreet way for victims to signal to pharmacy staff that they need...
Public list of companies in the UK who have had their licence/registration to manufacture or wholesale medicines/ingredients revoked or suspended.
List of manufacturers and their medical devices which have been granted an exemption by the MHRA. The list also includes manufacturers whose exemption expired or was cancelled. This information will be listed for 2 months after expiry or cancellation.
How to notify the MHRA of your intention to carry out a clinical investigation for medical devices.
How to make a payment to MHRA by credit or debit card or a bank transfer.
Guidance on managing and using bed rails safely.
How the ‘Written Confirmation’ process operates for active substances manufactured in Great Britain (England, Wales and Scotland).
How to get a parallel import licence for your medicine in the UK, including pharmacovigilance requirements and submitting your application.
Comply with good pharmacovigilance practice and prepare for an inspection.
List of field safety notices (FSNs) from medical device manufacturers from 04 January to 08 January 2021
The Consortium brings together 16 leading organisations, spanning the NHS, regulators, and leading third sector and charitable organisations
Information about the risks of taking valproate medicines during pregnancy.
Information for patients, healthcare professionals and developers of new medicines
A major initiative to ensure pregnant and breastfeeding women can make informed decisions about their healthcare
Information for healthcare professionals and the public about the COVID-19 Vaccine Moderna
The National Institute for Biological Standards and Control will carry out independent testing in the UK for any potential COVID-19 vaccines.
This guide has been provided to reduce the burden when preparing responses to Post Inspection Letters.
The vaccine has been approved after meeting the required safety, quality and effectiveness standards.
UK approved bodies listed under Medical Devices Regulations 2002 (SI 2002 No 618, as amended) (UK MDR 2002).
The medicine regulators from Australia, Canada, Singapore, Switzerland and the United Kingdom (Access Consortium) have discussed the regulatory evidence requirements for COVID-19 vaccine approvals and considerations for post-market pharmacovigilance.
The Access Consortium regulatory authorities have pledged our collective support in countering the COVID-19 global pandemic.
The Veterinary Medicines Directorate is recruiting one Non-Executive Director to the VMD’s Management Board and Audit and Risk Assurance Committee.
Report of the ten products for which most Special Import Certificates (SIC) have been issued by VMD in the UK.
Guidance for prescribing vets on the use of the cascade.
Marketing Authorisation Holders (MAHs) have informed the VMD of supply problems with the following lactating cow intramammary antibiotics.
How to legally run a business that deals with the wholesale of animal medicines (veterinary medicinal products) and the WDA Register.
Reporting against VMD published standards up to 31 March 2021
Details of seizure notice served following a parcel addressed to premises in Banbridge, County Down stopped at a Belfast Depot.
Details of seizure notice served following a parcel addressed to premises in Castlederg, County Tyrone stopped at a Belfast Depot.
A reminder about what to do when sending information and payments to the VMD whilst we continue to work remotely.
Definitive fees charged for applications under Schedule 7 of the Veterinary Medicines Regulations 2013.
Guidance for the pharmaceutical industry on importing and exporting veterinary medicines from 1 January 2021.
Guidance for the pharmaceutical industry on location and other authorised personnel requirements post transition period for existing marketing authorisations and applications submitted after 1 January 2021.
During the transition period, the Canada-EU Comprehensive Economic and Trade Agreement (CETA) continued to apply.
Explanation of what Pharmacovigilance means and who is responsible.
Guidance for the pharmaceutical industry on applying for an authorisation to manufacture veterinary medicines.
Guidance for the pharmaceutical industry on how to apply to vary a veterinary Marketing Authorisation (MA) or Homeopathic Remedy.
Guidance on the Batch Release Request scheme for an immunological veterinary medicine to be placed on the UK market.
Guidance for the pharmaceutical industry on Marketing Authorisations for veterinary medicines.
Guidance for the pharmaceutical industry on who can be a Marketing Authorisation Holder, named distributor or local representative and how to make changes to these.
Guidance for the pharmaceutical industry on how to apply for an authorisation to place a veterinary medicine on the UK market or part of, or to expire one.
Agreement will leverage Enara's novel Dark Antigen discovery platform
Ensinfentrine is a first-in-class inhaled inhibitor of the enzymes phosphodiesterase 3 and 4
In a Phase IIb trial, more patients experienced complete resolution of hives with ligelizumab compared to Xolair
Zejula has been recommended for use in newly diagnosed ovarian cancer patients
Qualified pharmacists will administer the Pfizer/BioNTech vaccine at an in-store pharmacy
First dispersible tablet formulation of Tivicay now available for children in the EU
Oxford Immunotec will perform T cell testing on participants receiving Valneva's vaccine candidate
Companies will collaborate on a combination therapy study
Updated analysis is from the Phase III IMbrave150 study
MHRA submission is based on same application filed with the EMA
Investigational antibody targets a modified form of beta amyloid called N3pG
First patient in global trial dosed in the UK
Study will evaluate the role of smart devices on monitoring cognitive health
CCS1477 has a novel mechanism of action compared to existing treatments
Framework identifies four key priorities and five 'underpinning themes'
Unit 2 Fleet Business Park, Sandy Lane, Church Crookham, Fleet, Hampshire, GU52 8BF
Pharmaceutical and Veterinary Licensed Distributor. WDA (H) 43703 & WDA (V) 43703.
- +44 (0)1252 260 460.
- +44 (0)1276 469 290
Monday to Friday - 09:30 – 18:30
Saturday & Sunday - Closed, Online Ordering Available
